ENTA - NASDAQ
Enanta Pharmaceuticals, Inc.
$11.90
-1.1%Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
At a Glance
Live Snapshotenta
Additional Paid-In Capital
Last Annual Value
469.77M
3-Year CAGR
6%
5-Year CAGR
8%
10-Year CAGR
7%
Enanta Pharmaceuticals, Inc. Competitors Analysis of Additional Paid-In Capital
| Company | Additional Paid-In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Enanta Pharmaceuticals, Inc. NASDAQ:ENTA | 469.77M | 3.4% | 6.0% | 6.9% | |
 Assembly Biosciences, Inc. NASDAQ:ASMB | 1.04B | 7.9% | 5.3% | 13.7% | |
 Immuneering Corporation NASDAQ:IMRX | 498.66M | 25.2% | 18.3% | N/A | |
 Sangamo Therapeutics, Inc. NASDAQ:SGMO | 1.61B | 2.6% | 3.8% | 10.8% | |
 Sagimet Biosciences Inc. NASDAQ:SGMT | 457.61M | 10.3% | 69.1% | N/A | |
 Entrada Therapeutics, Inc. NASDAQ:TRDA | 0.00 | N/A | N/A | N/A | |
 Ventyx Biosciences, Inc. NASDAQ:VTYX | 808.19M | 6.8% | 15.3% | N/A | |
 Zura Bio Limited NASDAQ:ZURA | 326.08M | 26.0% | N/A | N/A | |
 Tenaya Therapeutics, Inc. NASDAQ:TNYA | 728.25M | 10.3% | 10.9% | N/A | |
 Caribou Biosciences, Inc. NASDAQ:CRBU | 718.58M | 2.5% | 8.1% | N/A | |
 Atea Pharmaceuticals, Inc. NASDAQ:AVIR | 797.75M | 2.0% | 4.1% | N/A |
Enanta Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your ENTA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.